Publications

5532 Results

Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials

Authors
R Safyan;S Colby;C Figueroa-Moseley;K Guthrie;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
Year
2024
Research Committee(s)
Gastrointestinal

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel [Brief Report]

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;M LeBlanc;I Thompson;N Agarwal
Journal / Conference
Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38424319
Study Number(s)
S1216

Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide

Authors
M Parikh;C Tangen;M Hussain;S Gupta;Y Jo;S Callis;A Harzstark;C Paller;S George;M Zibelman;H Cheng;B Maughan;J Zhang;R Pachynski;A Bryce;D Lin;D Quinn;I Thompson;SP Lerner;T Dorff;P Lara;N Agarwal
Journal / Conference
European Urology Oncology Mar 23:S2588-9311(24)00054-3. doi: 10.1016/j.euo.2024.03.001. Online ahead of print
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38523017
Study Number(s)
S1216

SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)

Authors
V Sun;KA Guthrie;T Crane;K Arnold;S Colby;S Freylersythe;C Braun-Inglis;R Topacio;C Messick;J Carmichael;A Muskovitz;M Nashawaty;M Bajaj;S Cohen;D Flaherty;M O'Rourke;L Jones;R Krouse;C Thomson
Journal / Conference
Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
Year
2024
Research Committee(s)
Palliative and End of Life Care
PMID
PMID38386696
PMC
PMC11162313
Study Number(s)
S1820

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)

Authors
P Mittal;Y Yang;S Soni;F Battaglin;J Millstein;S Stintzing;A Parikh;J Lo;L Torres-Gonzalez;S Algaze;P Jayachandran;K Ashouri;A Wong;W Zhang;C Mancao;C Cremolini;V Heinemann;I Singh;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823

Authors
A Morin Coulombe;S Colby;J King;M Neuhouser;B Arun;S Daneshman;A Harzstark;K Arnold;C Nichols;L Nappi
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
Year
2024
Research Committee(s)
Prevention and Epidemiology
Study Number(s)
S1823

Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL

Authors
J Wolfson;A Grimes;M Nuno;C Kerber;S Ramakrishnan;M Beauchemin;D Dickens;J Levine;M Roth;M Scialla;W Woods;S Vargas;K Boayue;G Chang;W Stock;D Hershman;E Curran;A Advani;K O'Dwyer;S Luger;J Liu;D Freyer;L Sung;S Parsons
Journal / Conference
JCO Oncology Practice Apr;20(4):491-502
Year
2024
Research Committee(s)
Cancer Care Delivery
PMID
PMID38252911
PMC
PMC11085951

SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Authors
A Saeed;S Colby;P Oberstein;D Duda;R Agarwal;C Figeroa-Moseley;R Vaidya;J Unger;K Guthrie;F Rocha;M Senthil;R Safyan;Z Wainberg;S Iqbal;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
Year
2024
Research Committee(s)
Gastrointestinal

Postoperative Complications Following Neoadjuvant Therapy and Surgery in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

Authors
R Snyder;S Ahmad;D Segovia;T Zemla;Q Shi;E O'Reilly;J Herman;M Katz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA); J Clin Oncol 42, 2024 (suppl 3; abstr 664), poster
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021501

Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505

Authors
SH Patel;S Colby;D Sohal;K Guthrie;L Kachnic;E Chiorean;A Lowy;F Rocha;PA Philip;S Ahmad
Journal / Conference
Society of Surgical Oncology (March 20-23, 2024, Atlanta, GA) oral
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505